AI Pathology Firm Lunit Embeds Technology in Pharma Drug Trials Through Lab Services Deal
Korean medical AI company partners with Discovery Life Sciences to integrate its SCOPE platform into biomarker analysis workflows supporting over 350 active clinical trial programs.
Stockholm Replaces Human Radiologists with AI in Massive Breast Cancer Screening Overhaul
Sweden's capital region will deploy artificial intelligence as an independent second reader across 250,000 annual mammograms following a landmark study showing 15% higher cancer detection and dramatic efficiency gains.
AI Pathology Platform Predicts Which Bile Duct Cancer Patients Will Respond to Targeted Therapy
Lunit's SCOPE platform identified biomarkers that helped achieve 55% response rate in aggressive HER2-positive biliary tract cancer, earning publication in Nature Medicine.
The Hidden Inequity in Your Hospital's AI: Why Clinical Algorithms May Be Failing Vulnerable Patients
Australian experts reveal how biased training data in medical AI systems is perpetuating healthcare disparities, and what clinicians can do about it.
RadNet Wins FDA Nod for AI That Automates Breast Ultrasound Analysis From Detection to Report
The imaging giant's newly cleared artificial intelligence platform promises to streamline three critical steps in breast ultrasound interpretation, addressing workflow bottlenecks in women's imaging.
AI Pathology Giants Unite: How Eight Companies Plan to Reshape Drug Development from the Inside
South Korea's Lunit joins global consortium targeting the pharmaceutical value chain with AI-powered biomarker discovery and patient selection technologies.